We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Ensuring an organisation's activities are compliant with key regulations. Evidology is a software program that can be easily integrated into a business's existing infrastructure. The software will check the business's data against more than 40 local and international legislation's and provide a real-time report to management that will highlight whether the business is following compliance, or not. Evidology's revenue model consists of a 3-year subscription package, in the form of a standard, or enterprise-level product. The company has tested their software within nine businesses, including HSBC. Evidology has predicted to break even as soon as 15 months, based on selling their product at a modest rate of 3 clients per month.
days to go: Expired investment: £50,003
Novus aspires to become the UK's first ethical digital bank. It argues that Generation Z and millennials want purpose-driven products and services that can also address environmental and social challenges of the times. The company asserts that its services align with the aforementioned objective. Novus allows its members to live a sustainable lifestyle by providing them access to sustainable brands through Novus' in-app marketplace and rewarding them via cashbacks. The company intends to undergo two more funding rounds – Series A and Series B – for scaling its UK operations and expanding in the US and other key EU markets within the next two years. It will IPO its business when it achieves profitability. The company also foresees a strategic exit to interested banking entities.
days to go: Expired investment: £732,000
A thought leadership media platform working with trusted experts to bring innovative advancements to organisations through journalism. The Future Shapers aims to re-imagine how information is delivered globally and the ways it can help small to large communities innovate further, avoiding the use of advertisers and paywalls.
days to go: Expired investment: £41,610
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
Ablrate.com is an FCA regulated peer to peer lending platform which connects lenders with borrowers for asset-backed loans. It was launched in late 2014 and has a community of 5000 lenders who have completed £1 million+ worth of loans per month to all sizes of businesses throughout the UK.
days to go: Expired investment: £457,950
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph